{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-034049","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.089358+00:00","generated_at":"2026-05-30T02:50:51.186865+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Monopar reports Q3 net loss $1.3M; in-licensed Wilson disease drug ALXN-1840; raised $17.7M","bullets":["Net loss Q3 2024 $1.3M ($0.37/share) vs $2.0M ($0.69/share) Q3 2023.","Exclusive license from Alexion for ALXN-1840 (Wilson disease, Phase 3 completed); planning FDA discussions.","MNPR-101-Lu Phase 1a therapy trial active and enrolling in Australia; MNPR-101-Zr imaging trial shows tumor uptake.","Completed public offering Oct 30, 2024: 1,181,540 shares at $16.25/sh, net $17.7M.","Cash $6.0M at Sept 30; pro forma runway into first half 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-034049","json":"https://secwatch.observer/filing/0001437749-24-034049.json","markdown":"https://secwatch.observer/filing/0001437749-24-034049.md","text":"https://secwatch.observer/filing/0001437749-24-034049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924034049/0001437749-24-034049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924034049/mnpr20241107_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:50:51.186865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}